Skip to Content

RVL-1201 Approval Status

FDA Approved: No
Brand name: RVL-1201
Generic name: oxymetazoline hydrochloride
Dosage form: Ophthalmic Solution
Company: Vertical Pharmaceuticals, LLC
Treatment for: Blepharoptosis

RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a novel, once-daily ophthalmic formulation of the direct-acting α-adrenergic receptor agonist oxymetazoline, in development for the treatment of acquired blepharoptosis (droopy eyelid).

Development Status and FDA Approval Process for RVL-1201

DateArticle
Sep 17, 2019Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide